A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

- Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent. (Phase 2: Non-small cell lung cancer (NSCLC) (adenocarcinoma)). - Subjects who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or who refuse standard treatment. (Note: There is no limit to the number of prior treatment regimens). - Willingness to undergo pretreatment and on-treatment tumor biopsies (must allow for adequate sample of tissue from appropriate site). - Known active CNS metastases and/or carcinomatous meningitis. (Subjects with previously treated brain metastases permitted if stable).

Type of Study

Treatment

Locations

University of Colorado Hospital

Principal Investigator
Laura Medina,  MD

Laura Medina, MD

Study ID

Protocol Number: 21-4329

More information available at ClinicalTrials.gov: NCT03665285

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers